Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Prometheus Appoints CTO | Contract Pharma
Promotions & Moves

Prometheus Appoints CTO

Dr. Olivier Laurent will serve on the executive management team and will lead the company's early stage discovery initiatives.

Prometheus Biosciences, Inc., a biotechnology company pioneering a precision medicine and companion diagnostics for the treatment of inflammatory bowel disease (IBD), has appointed Olivier Laurent, Ph.D. as Chief Technology Officer. Dr. Laurent will serve on the executive management team and will lead the company’s early stage discovery initiatives.

“Dr. Laurent’s success in designing and developing biopharmaceuticals products across multiple therapeutic areas, including recombinant proteins and antibodies, is well aligned with our needs as we grow our GI medicines pipeline and our business,” said Mark McKenna, President and Chief Executive Officer, Prometheus Biosciences. 

Dr. Laurent most recently served as Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of solid tumors.  Prior to this position, Dr. Laurent spent twenty years designing and developing biopharmaceuticals at companies including Sanofi, Bayer HealthCare, Genentech, Pfizer, CovX (acquired by Pfizer in 2008) and Ambrx (acquired by a Chinese consortium in 2015). Dr. Laurent holds numerous patents in the field of biotherapeutics and has contributed to multiple antibody regulatory dossiers.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters